Xilio Therapeutics Incorporated is a biotech company that develops immunotherapies for cancer patients. Its inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. Xilio Therapeutics was founded in 2016 and is headquartered in Waltham, MA.
Name / Ticker | Price | Zen Rating |
---|---|---|
$7.83 | A | |
$43.37 | A | |
$22.12 | A |